期刊文献+

阿司匹林与低分子肝素联合治疗老年不稳定心绞痛疗效观察

下载PDF
导出
摘要 目的:观察阿司匹林联合低分子肝素治疗老年不稳定心绞痛疗效及安全性。方法:老年不稳定心绞痛61例随机分成两组,A组为常规治疗,给于口服阿司匹林100mg,日1次;B组:在A组基础上在腹壁皮下注射低分子肝素3000IU,12h1次。疗程均为2周。各组均给予硝酸酯类、ACEI类、钙拮抗剂或β受体阻滞剂。结果:两组总有效率分别为60%、92.1%,B组总有效率与A组比较差异有显著性(P<0.05),随访60d,B组急性心脏事件发生率与A组比较差异有显著性(P>0.05)。结论:阿司匹林与低分子肝素联合治疗老年不稳定心绞痛疗效确切、安全,能减少急性心脏事件发生率。
出处 《现代医药卫生》 2008年第7期987-987,共1页 Journal of Modern Medicine & Health
  • 相关文献

参考文献3

二级参考文献16

  • 1[1]Braunwald E, Antman EM. Beasley JW, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). J Am Coll Cardiol,2000,36:970-1062.
  • 2[2]Van der Wal AC, Becket AE, Koch KT, et al . Clinically stable angina pectoris is not necessarily associated with histologically stable atherosclerotic plaques. Heart, 1996, 76:312-316.
  • 3[3]Ryan TJ , Antman EM, Brooks NH, et al. 1999 Update:ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines(committee on Management of Acute Myocardial Infarction). J Am Call Cardiol, 1999, 34: 890-911.
  • 4[4]Markwardt F. Hirudin and derivatives as anticoagulant agents. Thromb Haemost, 1991,66:141-152.
  • 5[5]The FRAXIS Study Group. Comparison of two treatment durations(6 day and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina of non-Q wave myocardial infarction: FRAXIS( FRAXiparine in Ischemic Syndrome). Eur Heart J, 1999,20:1553-1562.
  • 6[6]Klein W, Buchwald A, Hillis SE, et al. Comparison of lowmolecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease, Fragmin in Unstable Coronary Artery Disease Study( FRIC). Circulation, 1997,96: 61-68.
  • 7[7]Wallentin L, Lagerqvist B, Husted S, et al. Outcome at 1 year after an invasive compared to a non-invasive strategy in unstable coronary artery disease: the FRISC Ⅱ invasive randomised trial. FRISC Ⅱ Investigators. Fast Revascularisation during Instability in Coronary Artery Disease. Lancet, 2000,356: 9-16.
  • 8[8]Frostfeldt G,Ahlberg G,Gustafsson G, et al. Low molecular weight heparin (dalteparin)as adjuvant treatment of thrombolysis in acute myocardial infarction-a pilot study:Biochemical Markers in Acute Coronary Syndromes (BIOMACSⅡ ). J Am Coll Cardiol,1999,33:627-633.
  • 9[9]Goodman SG, Cohen M, bigonzi F, et al. Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease :one-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events. J Am Coll Cardiol, 2000,36: 693-698.
  • 10[10]Antman EM, Mccabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the Thrombolysis in Myocardial Infarction ( TIMI )11B Trial.Circulation, 1999,100:1593-1601.

共引文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部